PMID- 35240681 OWN - NLM STAT- MEDLINE DCOM- 20220506 LR - 20240216 IS - 2473-9537 (Electronic) IS - 2473-9529 (Print) IS - 2473-9529 (Linking) VI - 6 IP - 9 DP - 2022 May 10 TI - A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. PG - 2757-2762 LID - 10.1182/bloodadvances.2021006801 [doi] AB - Polatuzumab vedotin (PV) is an antibody-drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included in the registration study, and reports of PV use after CAR T cells are limited. This multicenter retrospective analysis included patients with LBCL who relapsed or progressed after CAR T-cell therapy and subsequently received PV with or without rituximab and bendamustine between July 2019 and May 2021. Response to treatment and progression were assessed based on the 2014 Lugano criteria. Fifty-seven patients were included in the study: 18 (32%) patients were primary refractory to CAR T-cell therapy, and 34 (60%) patients received PV-based therapy immediately after CAR T-cell therapy. PV was combined with rituximab in 54 (95%) patients and administered with bendamustine in 35 (61%) patients. A response was achieved in 25 (44%) patients, including complete remission in 8 (14%). No significant association between baseline characteristics and response was observed. After a median follow-up of 47 weeks (95% confidence interval [CI], 40-54), 46 (81%) patients had disease progression or died, and the median progression-free survival was 10 weeks (95% CI, 5-15). On a multivariate analysis, bone marrow involvement (hazard ratio, 5.2; 95% CI, 1.8-15; P = .003) and elevated lactate dehydrogenase levels (hazard ratio, 5.0; 95% CI, 1.4-16; P = .01) were associated with shorter progression-free survival. Studies aimed at better characterizing the intrinsic mechanism of resistance and identifying optimal consolidation strategies for these patients are warranted. CI - (c) 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. FAU - Gouni, Sushanth AU - Gouni S AD - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Rosenthal, Allison C AU - Rosenthal AC AD - Division of Hematology-Oncology, Mayo Clinic, Phoenix, AZ. FAU - Crombie, Jennifer L AU - Crombie JL AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. FAU - Ip, Andrew AU - Ip A AD - John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ. FAU - Kamdar, Manali K AU - Kamdar MK AD - Blood Disorders Center, University of Colorado, Aurora, CO. FAU - Hess, Brian AU - Hess B AD - Division of Haematology, Medical University of South Carolina, Charleston, SC. FAU - Feng, Lei AU - Feng L AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Watson, Grace AU - Watson G AD - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Ayers, Amy AU - Ayers A AD - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Neelapu, Sattva S AU - Neelapu SS AUID- ORCID: 0000-0003-1045-4914 AD - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Khurana, Arushi AU - Khurana A AUID- ORCID: 0000-0001-5645-0949 AD - Division of Hematology, Mayo Clinic, Rochester, MN; and. FAU - Lin, Yi AU - Lin Y AD - Division of Hematology, Mayo Clinic, Rochester, MN; and. FAU - Iqbal, Madiha AU - Iqbal M AD - Division of Hematology, Mayo Clinic, Jacksonville, FL. FAU - Merryman, Reid W AU - Merryman RW AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. FAU - Strati, Paolo AU - Strati P AD - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Blood Adv JT - Blood advances JID - 101698425 RN - 0 (Antibodies, Monoclonal) RN - 0 (Immunoconjugates) RN - 4F4X42SYQ6 (Rituximab) RN - 981Y8SX18M (Bendamustine Hydrochloride) RN - KG6VO684Z6 (polatuzumab vedotin) SB - IM MH - Antibodies, Monoclonal MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bendamustine Hydrochloride/therapeutic use MH - Humans MH - *Immunoconjugates/adverse effects MH - Immunotherapy, Adoptive/adverse effects MH - *Lymphoma, Large B-Cell, Diffuse/drug therapy MH - Neoplasm Recurrence, Local/drug therapy MH - Retrospective Studies MH - Rituximab/adverse effects PMC - PMC9092406 EDAT- 2022/03/04 06:00 MHDA- 2022/05/07 06:00 PMCR- 2022/04/29 CRDT- 2022/03/03 20:21 PHST- 2021/12/09 00:00 [received] PHST- 2022/02/25 00:00 [accepted] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/05/07 06:00 [medline] PHST- 2022/03/03 20:21 [entrez] PHST- 2022/04/29 00:00 [pmc-release] AID - 484264 [pii] AID - 2022/ADV2021006801 [pii] AID - 10.1182/bloodadvances.2021006801 [doi] PST - ppublish SO - Blood Adv. 2022 May 10;6(9):2757-2762. doi: 10.1182/bloodadvances.2021006801.